BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Classen Immunotherapies Inc. Files Patent Infringement Suit Against King Pharmaceuticals And Elan Corporation PLC (ELN); Classen Initiates Program For Early Generic Introduction Of The Defendants' Drugs


10/19/2005 5:12:18 PM

BALTIMORE, Nov. 29 /PRNewswire/ -- Classen Immunotherapies, Inc. announces it has filed a patent infringement suit against King Pharmaceuticals, Inc. (Bristol, Tennessee), Elan Pharmaceuticals, Inc. (South San Francisco, California) and Elan Corporation, PLC (Dublin, Ireland) alleging the companies have infringed Classen Immunotherapies' patented processes directed to the discovery, analysis and commercialization of adverse drug event information. The complaint alleges that the defendants have sold more than $500 million worth of products - specifically, the muscle relaxant Skelaxin(R) (metaxalone) - that infringe Classen Immunotherapies' United States Patents Nos. 6,584,472 and 6,219,674.

Classen Immunotherapies has expertise in the area of discovering adverse event information that drug manufacturers are required to disclose.

More than two years after Classen Immunotherapies filed the application that resulted in U.S. Patent No. 6,219,674, Elan filed for and obtained two patents relating to new methods of use for metaxalone, including methods involving the disclosure of drug interaction events. King subsequently purchased the Elan patents and has used them in its efforts to remain the exclusive provider of Skelaxin(R). "King and Elan have proven that one can obtain a strong competitive advantage by patenting the disclosure of drug safety information," says Dr. J. Barthelow Classen, CEO of Classen Immunotherapies. "In this instance, however, we believe the methods used by King, Elan and their customers with respect to Skelaxin(R) fall within the scope of our earlier-filed patents."

For additional information concerning the lawsuit, please contact counsel for Classen Immunotherapies, Matthew G. McAndrews of Chicago-based Niro, Scavone, Haller & Niro, at (312) 236-0733 or e-mail mmcandrews@nshn.com.

Skelaxin(R) is a registered trademark of Elan Pharmaceuticals.

Classen Immunotherapies, Inc.

CONTACT: Matthew G. McAndrews of Niro, Scavone, Haller & Niro,+1-312-236-0733 or e-mail mmcandrews@nshn.com, for Classen Immunotherapies



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES